The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 65 , ISSUE 2 ( April-June, 2023 ) > List of Articles

REVIEW ARTICLE

Respiratory Involvement in Parkinson's Disease

Malay Sarkar, Jasmine Sarkar

Keywords : Aspiration pneumonia, Parkinson's disease, Respiratory dysfunction, Upper airway obstruction

Citation Information : Sarkar M, Sarkar J. Respiratory Involvement in Parkinson's Disease. Indian J Chest Dis Allied Sci 2023; 65 (2):74-82.

DOI: 10.5005/jp-journals-11007-0078

License: CC BY-NC 4.0

Published Online: 01-11-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Respiratory dysfunctions in patients with Parkinson's disease (PD) are common and are associated with increased mortality and morbidity. Respiratory dysfunctions have been described in patients with PD since the first observations of the disease by James Parkinson in 1817. Respiratory dysfunctions are multifaceted; obstructive ventilatory dysfunction includes upper airway obstruction (UAO), restrictive ventilatory dysfunction, respiratory muscle weakness, abnormalities in respiratory rhythm genesis, kyphosis, aspiration pneumonia, and side effects of medication. Many of the respiratory symptoms occur in the early stages of the disease. Respiratory dysfunction may predate motor symptoms by several years. Patients with PD usually do not complain about respiratory symptoms due to their sedentary lifestyle. The mechanisms of respiratory dysfunction in PD are evolving. This review will discuss various respiratory abnormalities that are associated with PD.

HTML PDF Share
  1. Pokusa M, Hajduchova D, Buday T, et al. Respiratory function and dysfunction in parkinson-type neurodegeneration. Physiol Res 2020;69(Suppl 1):S69–S79. DOI: 10.33549/physiolres.934405.
  2. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72(5):432–438. DOI: 10.1212/01.wnl.0000341769.50075.bb.
  3. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995;45(12):2143–2146. DOI: 10.1212/wnl.45.12.2143.
  4. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384–386. DOI: 10.1212/01.wnl.0000247740.47667.03.
  5. Zesiewicz TA, Baker ML, Wahba M, et al. Autonomic nervous system dysfunction in Parkinson's disease. Curr Treat Options Neurol 2003;5(2):149–160. DOI: 10.1007/s11940-003-0005-0.
  6. Wang Y, Shao WB, Gao L, et al. Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy-comparison with normal elderly. PloS One 2014;9(12):e116123. DOI: 10.1371/journal.pone.0116123.
  7. Du XY, Xie XX, Liu RT. The role of α-synuclein oligomers in Parkinson's Disease. Int J Mol Sci 2020;21(22):8645. DOI: 10.3390/ijms21228645.
  8. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223–236. DOI: 10.1176/jnp.14.2.223.
  9. Mark MH. Lumping and splitting the Parkinson Plus syndromes: Dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration. Neurol Clin 2001;19(3):607–627. DOI: 10.1016/s0733-8619(05)70037-2.
  10. Sabaté M, González I, Ruperez F, et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci 1996;138(1–2):114–119. DOI: 10.1016/0022-510x(96)00003-2.
  11. Vincken WG, Gauthier SG, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders. N Engl J Med 1984;311:438–442. DOI: 10.1056/NEJM198408163110704.
  12. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005;20(9):1104–1108. DOI: 10.1002/mds.20485.
  13. Tan LC, Tan AK, Tjia HT. The profile of hospitalised patients with Parkinson's disease. Ann Acad Med Singapore 1998;27(6):808–812. PMID: 10101555.
  14. O'Callaghan A, Walker R. A review of pulmonary function in Parkinson's disease. J Park Restless Legs Syndr 2018;8:13–23. DOI: 10.2147/JPRLS.S114309.
  15. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427–442. DOI: 10.1212/WNL.17.5.427.
  16. Braga M, Pederzoli M, Antonini A, et al. Reasons for hospitalization in Parkinson's disease: A case-control study. Parkinsonism Relat Disord 2014;20(5):488–492. DOI: 10.1016/j.parkreldis.2014.01.022.
  17. Neu HC, Connolly JJ Jr, Schwertley FW, et al. Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Respir Dis 1967;95(1):33–47. DOI: 10.1164/arrd.1967.95.1.33.
  18. Lilker ES, Woolf CR. Pulmonary function in Parkinson's syndrome: The effect of thalamotomy. Can Med Assoc J 1968;99(15):752–757. PMID: 5700845.
  19. Hovestadt A, Bogaard JM, Meerwaldt JD, et al. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52(3): 329–333. DOI: 10.1136/jnnp.52.3.329.
  20. Shill H, Stacy M. Respiratory complications of Parkinson's disease. Semin Respir Crit Care Med 2002;23(3):261–265. DOI: 10.1055/s-2002-33034.
  21. Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson's disease. Chest 2001;119(2):387–393. DOI: 10.1378/chest.119.2.387.
  22. Sabino-Carvalho JL, Fisher JP, Vianna LC. Autonomic function in patients with Parkinson's disease: From rest to exercise. Front Physiol 2021;12:626640. DOI: 10.3389/fphys.2021.626640.
  23. Izquierdo-Alonso JL, Jimenez-Jimenez FJ, Cabrera-Valdivia F, et al. Airway dysfunction in patients with Parkinson's disease. Lung 1994;172:47–55. DOI: 10.1007/BF00186168.
  24. De Pandis MF, Starace A, Stefanelli F, et al. Modification of respiratory function parameters in patients with severe Parkinson's disease. Neurol Sci 2002;23 (Suppl 2): s69–s70. DOI: 10.1007/s100720200074.
  25. Sathyaprabha TN, Kapavarapu PK, Pal PK, et al. Pulmonary functions in Parkinson's disease. Indian J Chest Dis Allied Sci 2005;47:251–257. PMID: 16255396.
  26. Torsney KM, Forsyth D. Respiratory dysfunction in Parkinson's disease. J Royal Coll Phys Edin 2017;47:35–39. DOI: 10.4997/jrcpe. 2017.108.
  27. Ruttiman R, Eltorai AEM, Daniels AH. Etiology and management of spinal deformity in patients with Parkinson's disease. Int J Spine Surg 2018;12(1):15–21. DOI: 10.14444/5003.
  28. Köseoğlu F, Inan L, Ozel S, et al. The effects of a pulmonary rehabilitation program on pulmonary function tests and exercise tolerance in patients with Parkinson's disease. Funct Neurol 1997;12(6):319–325. PMID: 9503194.
  29. Docu Axelerad A, Stroe AZ, Arghir OC, et al. Respiratory dysfunctions in Parkinson's disease patients. Brain Sci 2021;11(5):595. DOI: 10.3390/brainsci11050595.
  30. Sanches VS, Santos FM, Fernandes JM, et al. Neurodegenerative disorders increase decline in respiratory muscle strength in older adults. Respir Care 2014;59(12):1838–1845. DOI: 10.4187/respcare.03063.
  31. Baille G, Perez T, Devos D, et al. Early occurrence of inspiratory muscle weakness in Parkinson's disease. PLoS One 2018;13(1):e0190400. DOI: 10.1371/journal.pone.0190400.
  32. Estenne M, Hubert M, De Troyer A. Respiratory-muscle involvement in Parkinson's disease. N Engl J Med 1984;311:1516–1517. DOI: 10.1056/NEJM198412063112314.
  33. Zhang W, Zhang L, Zhou N, et al. Dysregulation of respiratory center drive (P0.1) and muscle strength in patients with early stage idiopathic Parkinson's disease. Front Neurol 2019;10:724. DOI: 10.3389/fneur.2019.00724.
  34. Pal PK, Sathyaprabha TN, Tuhina P, et al. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa. Mov Disord 2007;22(3):420–424. DOI: 10.1002/mds.21330.
  35. Kaminsky DA, Grosset DG, Kegler-Ebo DM, et al. Natural history of lung function over one year in patients with Parkinson's disease. Respir Med 2021;182:106396. DOI: 10.1016/j.rmed.2021.106396.
  36. Tzelepis GE, McCool FD, Friedman JH, et al. Respiratory muscle dysfunction in Parkinson's disease. Am Rev Respir Dis 1988;138(2): 266–271. DOI: 10.1164/ajrccm/138.2.266.
  37. Sabaté M, Rodríguez M, Méndez E, et al. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Arch Phys Med Rehabil 1996;77(1):29–34. DOI: 10.1016/S0003-9993(96)90216-6.
  38. Ferreira FV, Cielo CA, Trevisan ME. Respiratory, posture and vocals features in Parkinson's disease: Theoretical considerations [Article in Portuguese]. Rev CEFAC 2011;13(3):534–540. DOI: 10.1590/S1516-18462010005000135.
  39. Ramos ML, Neves DR, Lima VP, et al. Analysis of pneumofunctional parameters in patients with Parkinson's disease: Pilot study [Article in Portuguese]. Rev Bras Neurol 2014;50(2):38–43. DOI: https://doi.org/10.1590/1806-3713/e20180148.
  40. Lee MA, Prentice WM, Hildreth AJ, et al. Measuring symptom load in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2007;13(5):284–289. DOI: 10.1016/j.parkreldis.2006.11.009.
  41. Onodera H, Okabe S, Kikuchi Y, et al. Impaired chemosensitivity and perception of dyspnoea in Parkinson's disease. Lancet 2000;356: 739–740. DOI: 10.1016/S0140-6736(00)02638-6.
  42. Seccombe LM, Giddings HL, Rogers PG, et al. Abnormal ventilatory control in Parkinson's disease–further evidence for non-motor dysfunction. Respir Physiol Neurobiol 2011;179(2–3):300–304. DOI: 10.1016/j.resp.2011.09.012.
  43. Monteiro L, Souza-Machado A, Valderramas S, et al. The effect of levodopa on pulmonary function in Parkinson's disease: A systematic review and meta-analysis. Clin Ther 2012;34(5):1049–1055. DOI: 10.1016/j.clinthera.2012.03.001.
  44. Oliveira LM, Baertsch NA, Moreira TS, et al. Unraveling the mechanisms underlying irregularities in inspiratory rhythm generation in a mouse model of Parkinson's Disease. J Neurosci 2021;41(21):4732–4747. DOI: 10.1523/JNEUROSCI.2114-20.2021.
  45. Gardner WN, Langdon N, Parkes JD. Breathing in Parkinson's disease. Adv Neurol 1987;45:271–274. PMID: 3825700.
  46. Anderson TM, Garcia AJ 3rd, Baertsch NA, et al. A novel excitatory network for the control of breathing. Nature 2016;536(7614):76–80. DOI: 10.1038/nature18944.
  47. Del Negro CA, Funk GD, Feldman JL. Breathing matters. Nat Rev Neurosci 2018;19(6):351–367. DOI: 10.1038/s41583-018-0003-6.
  48. Johnson SM, Smith JC, Feldman JL. Modulation of respiratory rhythm in vitro: role of Gi/o protein-mediated mechanisms. J Appl Physiol (1985) 1996;80(6):2120–2133. DOI: 10.1152/jappl.1996.80.6.2120.
  49. Oliveira LM, Oliveira MA, Moriya HT, et al. Respiratory disturbances in a mouse model of Parkinson's disease. Exp Physiol 2019;104(5):729–739. DOI: 10.1113/EP087507.
  50. Lee SY, Chen MH, Chiang PL, et al. Reduced gray matter volume and respiratory dysfunction in Parkinson's disease: A voxel-based morphometry study. BMC Neurol 2018;18(1):73. DOI: 10.1186/s12883-018-1074-8.
  51. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197–211. DOI: 10.1016/S0197-4580(02)00065-9.
  52. Jankovic J, Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology 1986;36(2):303–304. DOI: 10.1212/WNL.36.2.303-b.
  53. Kruk J, Sachdev P, Singh S. Neuroleptic-induced respiratory dyskinesia. J Neuropsychiatry Clin Neurosci 1995;7(2):223–229. DOI: 10.1176/jnp.7.2.223.
  54. Weiner WJ, Goetz CG, Nausieda PA, et al. Respiratory dyskinesias: Extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978;88(3):327–331. DOI: 10.7326/0003-4819-88-3-327.
  55. Onoue H, Yukitake M, Kurohara K, et al. A case report of Parkinson's disease presenting with recurrent dyspneic attacks due to focal laryngeal dystonia. Rinsho Shinkeigaku 2003;43:192–194.
  56. Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2002;17(3):524–527. DOI: 10.1002/mds.10072.
  57. Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996;47(5):1180–1183. DOI: 10.1212/WNL.47. 5.1180.
  58. Raja K, Ramrakhia S, Dev K, et al. The risk factors for the wearing-off phenomenon in Parkinson's disease. Cureus 2020;12(9):e10729. DOI: 10.7759/cureus.10729.
  59. Khan W, Naz S, Rana AQ. Shortness of breath, a ‘wearing-off’ symptom in Parkinson's disease. Clin Drug Investig 2009;29(10):689–691. DOI: 10.2165/11315290-000000000-00000.
  60. Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord 2001;8(2):109–121. DOI: 10.1016/S1353-8020(01)00025-6.
  61. Kelly B, Blake C, Lennon O. Acute hospital admissions of individuals with a known parkinson's disease diagnosis in Ireland 2009–2012: A short report. J Parkinsons Dis 2016;6(4):709–716. DOI: 10.3233/JPD-160839.
  62. Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson's disease and matched controls in North Wales, UK at 18 years: A community-based cohort study. BMJ Open 2018;8(2):e018969. DOI: 10.1136/bmjopen-2017-018969.
  63. Hely MA, Morris JG, Traficante R, et al. The sydney multicentre study of Parkinson's disease: Progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67(3):300–307. DOI: 10.1136/jnnp.67.3.300.
  64. Akbar U, Dham B, He Y, et al. Incidence and mortality trends of aspiration pneumonia in Parkinson's disease in the United States, 1979–2010. Parkinsonism Relat Disord 2015;21(9):1082–1086. DOI: 10.1016/j.parkreldis.2015.06.020
  65. Won JH, Byun SJ, Oh BM, et al. Risk and mortality of aspiration pneumonia in Parkinson's disease: A nationwide database study. Sci Rep 2021;11:6597. DOI: 10.1038/s41598-021-86011-w.
  66. Pennington S, Snell K, Lee M, et al. The cause of death in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010;16(7):434–37. DOI: 10.1016/j.parkreldis.2010.04.010.
  67. Bine JE, Frank EM, McDade HL. Dysphagia and dementia in subjects with Parkinson's disease. Dysphagia 1995;10(3):160–164. DOI: 10.1007/BF00260970.
  68. Lieberman AN, Horowitz L, Redmond P, et al. Dysphagia in Parkinson's disease. Am J Gastroenterol 1980;74(2):157–160. PMID: 6778203.
  69. Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19(3):283–287. DOI: 10.1002/ana.410190310.
  70. Wheeler Hegland K, Troche MS, et al. Comparison of voluntary and reflex cough effectiveness in Parkinson's disease. Parkinsonism Relat Disord 2014;20(11):1226–1230. DOI: 10.1016/j.parkreldis.2014.09.010
  71. Hegland KW, Okun MS, Troche MS. Sequential voluntary cough and aspiration or aspiration risk in Parkinson's disease. Lung 2014;192(4):601–608. DOI: 10.1007/s00408-014-9584-7.
  72. Chang YP, Yang CJ, Hu KF, et al. Risk factors for pneumonia among patients with Parkinson's disease: A Taiwan nationwide population-based study. Neuropsychiatr Dis Treat 2016;12:1037–1046. DOI: 10.2147/NDT.S99365.
  73. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;317(8210):44. DOI: 10.1016/S0140-6736(81)90150-1.
  74. Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996;9:1013–1019. DOI: 10.1183/09031936.96.09051013.
  75. Marsaudon E, Castet D, Barrault MF, et al. Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine. Rev Mal Respir 1997;14(5):405–407. PMID: 9480488.
  76. Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30(4):613–616. DOI: 10.1002/ana.410300416.
  77. Melmed S, Braunstein G. Bromocriptine and Pleuropulmonary disease. Arch Intern Med 1989;149:258–259. DOI: 10.1001/archinte.1989.00390020008002.
  78. Tintner R, Manian P, Gauthier P, et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol 2005;62(8):1290–1295. DOI: 10.1001/archneur.62.8.1290.
  79. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999;116:212–221. DOI: 10.1378/chest.116.1.212.
  80. Comet R, Domingo C, Such JJ, et al. Pleuropulmonary disease as a side-effect of treatment with bromocriptine. Respir Med 1998;92(9):1172–1174. DOI: 10.1016/S0954-6111(98)90415-2.
  81. Tolar M, Gorelick R, Feldman R. Constrictive pericarditis in Parkinson's disease patients treated with pergolide [abstract]. Ann Neurol 2001;50:S32. DOI: 10.1002/ana.1172.
  82. Erton ML, Ilker YN, Ceyhan N, et al. Retroperitoneal fibrosis due to malignancy: a case report. Int Urol Nephrol 1995;27:147–150. DOI: 10.1007/BF02551311.
  83. Gram TE. Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol Rev 1997;49:297–341. PMID: 9443161.
  84. Debove P, Simon F, Vaylet F, et al. Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case. Ann Med Interne (Paris) 1998;149(3):167–171. PMID: 11490541.
  85. Seppi K, Ray Chaudhuri K, Coelho M et al. Update on treatments for nonmotor symptoms of Parkinson's disease—An evidence based medicine review. Mov Disord 2019;34(2):180–198. DOI: 10.1002/mds.27602.
  86. Factor SA, McAlarney T, Sanchez-Ramos JR, et al. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5(4):280–285. DOI: 10.1002/mds.870050404.
  87. Barone P, Antonini A, Colosimo C, et al. The Priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24(11):1641–49. DOI: 10.1002/mds.22643.
  88. Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 2008;23(1):35–41. DOI: 10.1002/mds.21727.
  89. Kalaitzakis ME, Gentleman SM, Pearce RKB. Disturbed sleep in Parkinson's disease: Anatomical and pathological correlates. Neuropathol Appl Neurobiol 2013;39(6):644–653. DOI: 10.1111/nan.12024.
  90. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series. Sleep Med 2013;14(8):744–748. DOI: 10.1016/j.sleep.2012.10.009.
  91. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12(5):443–453. DOI: 10.1016/S1474-4422(13)70056-5.
  92. Suzuki K, Miyamoto M, Miyamoto T, et al. Parkinson's disease and sleep/wake disturbances. Curr Neurol Neurosci Rep 2015;15(3):8. DOI: 10.1007/s11910-015-0525-5.
  93. Swift CG, Shapiro CM. Sleep and sleep problems in elderly people. BMJ 1993;306:1468–1471. DOI: 10.1136/bmj.306.6890.1468.
  94. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease epidemiology and management. CNS Drugs 2001;15(4):267–275. DOI: 10.2165/00023210-200115040-00002.
  95. Nedergaard M, Goldman SA. BRAIN DRAIN. Sci Am 2016;314(3):44–49. DOI: 10.1038/scientificamerican0316-44.
  96. Gjerstad MD, Wentzel-Larsen T, Aarsland D, et al. Insomnia in Parkinson's disease: Frequency and progression over time. J Neurol Neurosurg Psychiatry 2007;78(5):476–479. DOI: 10.1136/jnnp.2006.100370.
  97. Bohnen NI, Hu MTM. Sleep disturbance as potential risk and progression factor for Parkinson's disease. J Parkinsons Dis 2019;9(3):603–614. DOI: 10.3233/JPD-191627.
  98. Falup-Pecurariu C, Diaconu Ş. Sleep dysfunction in Parkinson's disease. Int Rev Neurobiol 2017;133:719–742. DOI: 10.1016/bs.irn.2017.05.033.
  99. Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson's disease. Parkinsonism Relat Disord 2016;33:51–57. DOI: 10.1016/j.parkreldis.2016.09.010.
  100. Lima M. Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation. Sleep Med Rev 2013;17:367–375. DOI: 10.1016/j.smrv.2012.10.006.
  101. Adler C, Thorpy M. Sleep issues in Parkinson's disease. Neurology 2005;64(Suppl 3):S13–S20. DOI: 10.1212/WNL.64.12_suppl_3.S12.
  102. Loddo G, Calandra-Buonaura G, Sambati L, et al. The treatment of sleep disorders in Parkinson's disease: From research to clinical practice. Frontiers Neurol 2017;8:42. DOI: 10.3389/fneur.2017.00042.
  103. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895–899. DOI: 10.1002/mds.870130606.
  104. Tholfsen LK, Larsen JP, Schulz J, et al. Changes in insomnia subtypes in early Parkinson disease. Neurology 2017;88:352–358. DOI: 10.1212/WNL.0000000000003540.
  105. Videnovic A. Disturbances of sleep and alertness in Parkinson's disease. Curr Neurol Neurosci Rep 2018;18(6):29. DOI: 10.1007/s11910-018-0838-2.
  106. American Academy of Sleep Medicine. Darien, IL: American Academy of Sleep Medicine; 2014. International Classification of Sleep Disorders III.
  107. Kumar S, Bhatia M, Behari M. Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS). Sleep Med 2003;4(4):339–342. DOI: 10.1016/S1389-9457(03)00105-9.
  108. Pal S, Bhattacharya KF, Agapito C, et al. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001;108(1):71–77. DOI: 10.1007/s007020170098.
  109. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9(3):185–200. DOI: 10.1016/j.smrv.2005.01.001.
  110. Gjerstad MD, Alves G, Wentzel-Larsen T, et al. Excessive daytime sleepiness in Parkinson disease: Is it the drugs or the disease? Neurology 2006;67:853–858. DOI: 10.1212/01.wnl.0000233980.25978.9d.
  111. Knie B, Mitra MT, Logishetty K, et al. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 2011;25(3):203–212. DOI: 10.2165/11539720-000000000-00000.
  112. Schrempf W, Brandt MD, Storch A, et al. Sleep disorders in Parkinson's disease. J Parkinsons Dis 2014;4(2):211–221. DOI: 10.3233/JPD-130301.
  113. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: Demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331–339. DOI: 10.1093/brain/123.2.331.
  114. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46(2):388–93. DOI: 10.1212/WNL.46.2.388.
  115. Zhang J, Xu CY, Liu J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. BMC Neurol 2017;17(1):23. DOI: 10.1186/s12883-017-0795-4.
  116. Kim YE, Jeon BS. Clinical implication of REM sleep behavior disorder in Parkinson's disease. J Parkinsons Dis 2014;4(2):237–244. DOI: 10.3233/JPD-130293.
  117. Kim Y, Kim YE, Park EO, et al. REM sleep behavior disorder portends poor prognosis in Parkinson's disease: A systematic review. J Clin Neurosci 2018;47:6–13. DOI: 10.1016/j.jocn.2017.09.019.
  118. Lee JE, Shin HW, Kim KS, et al. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009;24:579–582. DOI: 10.1002/mds.22410.
  119. Yang X, Liu B, Shen H, et al. Prevalence of restless legs syndrome in Parkinson's disease: A systematic review and meta-analysis of observational studies. Sleep Med 2018;43:40–46. DOI: 10.1016/j.sleep.2017.11.1146.
  120. Fereshtehnejad SM, Rahmani A, Shafieesabet M, et al. Prevalence and associated comorbidities of restless legs syndrome (RLS): Data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran. PLoS ONE 2017;12(2):e0172593. DOI: 10.1371/journal.pone.0172593.
  121. Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 2011;77(22):1941–1946. DOI: 10.1212/WNL.0b013e31823a0cc8.
  122. Hornyak M, Feige B, Riemann D, et al. Periodic leg movements in sleep and periodic limb movement disorder: Prevalence, clinical significance and treatment. Sleep Med Rev 2006;10(3):169–177. DOI: 10.1016/j.smrv.2005.12.003.
  123. Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, et al. High frequency of sleep disorders in Parkinson's disease and its relationship with quality of life. Eur Neurol 2017;78(5–6):330–337. DOI: 10.1159/000481939.
  124. Sun AP, Liu N, Zhang YS, et al. The relationship between obstructive sleep apnea and Parkinson's disease: A systematic review and meta-analysis. Neurol Sci 2020;41(5):1153–1162. DOI: 10.1007/s10072-019-04211-9.
  125. Kaminska M, Lafontaine AL, Kimoff RJ. The interaction between obstructive sleep apnea and Parkinson's disease: Possible mechanisms and implications for cognitive function. Parkinsons Dis 2015;2015:849472. DOI: 10.1155/2015/849472.
  126. Elfil M, Bahbah EI, Attia MM, et al. Impact of obstructive sleep apnea on cognitive and motor functions in Parkinson's Disease. Mov Disord 2021;36(3):570–580. DOI: 10.1002/mds.28412.
  127. Arnulf I, Derenne JP. Respiratory disorders during sleep in degenerative diseases of the brain stem [in French]. Rev Neurol (Paris) 2001;157:S148–S151. PMID: 11924029.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.